112 related articles for article (PubMed ID: 31173157)
41. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.
Wang L; Fang D; Xu J; Luo R
BMC Cancer; 2020 Nov; 20(1):1059. PubMed ID: 33143662
[TBL] [Abstract][Full Text] [Related]
42. How zoledronic acid improves osteoporosis by acting on osteoclasts.
Wang B; Zhan Y; Yan L; Hao D
Front Pharmacol; 2022; 13():961941. PubMed ID: 36091799
[TBL] [Abstract][Full Text] [Related]
43. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.
Huang XL; Huang LY; Cheng YT; Li F; Zhou Q; Wu C; Shi QH; Guan ZZ; Liao J; Hong W
Int J Mol Med; 2019 Aug; 44(2):582-592. PubMed ID: 31173157
[TBL] [Abstract][Full Text] [Related]
44. Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.
Huang XL; Liu C; Shi XM; Cheng YT; Zhou Q; Li JP; Liao J
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34935053
[TBL] [Abstract][Full Text] [Related]
45. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
46. Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.
Lin W; Li XF; Ren DC; Song M; Duan L; Liu JZ; Zhan ZR
Mol Med; 2021 Feb; 27(1):19. PubMed ID: 33637048
[TBL] [Abstract][Full Text] [Related]
47. Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways.
Yin Z; Zhu W; Wu Q; Zhang Q; Guo S; Liu T; Li S; Chen X; Peng D; Ouyang Z
Eur J Pharmacol; 2019 Sep; 859():172550. PubMed ID: 31323222
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of zoledronic acid derivatives with extended methylene linkers on osteoclastogenesis involve downregulation of JNK and Akt pathways.
Peng Y; Liu Q; Xu D; Li K; Li H; Qiu L; Lin J
Cell Biol Int; 2021 May; 45(5):1015-1029. PubMed ID: 33404170
[TBL] [Abstract][Full Text] [Related]
49. Bone-targeting drug delivery system of biomineral-binding liposomes loaded with icariin enhances the treatment for osteoporosis.
Sun X; Wei J; Lyu J; Bian T; Liu Z; Huang J; Pi F; Li C; Zhong Z
J Nanobiotechnology; 2019 Jan; 17(1):10. PubMed ID: 30670021
[TBL] [Abstract][Full Text] [Related]
50. [The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].
Yasuda H
Nihon Yakurigaku Zasshi; 2019; 153(1):11-15. PubMed ID: 30643086
[TBL] [Abstract][Full Text] [Related]
51. Tatarinan N inhibits osteoclast differentiation through attenuating NF-κB, MAPKs and Ca
Zhang Y; Wang Z; Xie X; Wang J; Wang Y; Peng QS; Zhang M; Wu D; Liu N; Wang HB; Sun WC
Int Immunopharmacol; 2018 Dec; 65():199-211. PubMed ID: 30316078
[TBL] [Abstract][Full Text] [Related]
52. T63 inhibits osteoclast differentiation through regulating MAPKs and Akt signaling pathways.
Zhao XL; Chen JJ; Si SY; Chen LF; Wang Z
Eur J Pharmacol; 2018 Sep; 834():30-35. PubMed ID: 30012501
[TBL] [Abstract][Full Text] [Related]
53. Effect of l-caldesmon on osteoclastogenesis in RANKL-induced RAW264.7 cells.
Liou YM; Chan CL; Huang R; Wang CA
J Cell Physiol; 2018 Sep; 233(9):6888-6901. PubMed ID: 29377122
[TBL] [Abstract][Full Text] [Related]
54. Reactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells.
Tai TW; Chen CY; Su FC; Tu YK; Tsai TT; Lin CF; Jou IM
Sci Rep; 2017 Mar; 7():44245. PubMed ID: 28281643
[TBL] [Abstract][Full Text] [Related]
55. Methyl Gallate Inhibits Osteoclast Formation and Function by Suppressing Akt and Btk-PLCγ2-Ca
Baek JM; Kim JY; Lee CH; Yoon KH; Lee MS
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272351
[TBL] [Abstract][Full Text] [Related]
56. Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic differentiation through inhibiting the RANKL-Erk1/2 signaling pathway.
Yuan M; Chen J; Zeng Z
Mol Med Rep; 2016 Dec; 14(6):5199-5204. PubMed ID: 27779672
[TBL] [Abstract][Full Text] [Related]
57. Tatarinan O, a lignin-like compound from the roots of Acorus tatarinowii Schott inhibits osteoclast differentiation through suppressing the expression of c-Fos and NFATc1.
Xu X; Liu N; Wang Y; Pan LC; Wu D; Peng Q; Zhang M; Wang HB; Sun WC
Int Immunopharmacol; 2016 May; 34():212-219. PubMed ID: 26971224
[TBL] [Abstract][Full Text] [Related]
58. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.
Zeng XZ; He LG; Wang S; Wang K; Zhang YY; Tao L; Li XJ; Liu SW
Acta Pharmacol Sin; 2016 Feb; 37(2):255-63. PubMed ID: 26592521
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of Osteoclast Differentiation by Ginsenoside Rg3 in RAW264.7 Cells via RANKL, JNK and p38 MAPK Pathways Through a Modulation of Cathepsin K: An In Silico and In Vitro Study.
Siddiqi MH; Siddiqi MZ; Kang S; Noh HY; Ahn S; Simu SY; Aziz MA; Sathishkumar N; Jiménez Pérez ZE; Yang DC
Phytother Res; 2015 Sep; 29(9):1286-1294. PubMed ID: 26059856
[TBL] [Abstract][Full Text] [Related]
60. Effect of zoledronic acid on spinal fusion outcomes in an ovariectomized rat model of osteoporosis.
Yasen M; Li X; Jiang L; Yuan W; Che W; Dong J
J Orthop Res; 2015 Sep; 33(9):1297-304. PubMed ID: 26011820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
